Radar · Oncology in Massachusetts
Best Oncology Companies in Massachusetts, United States
The 416 best Oncology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
By Riya SenguptaFinancials
416companies tracked
$29.8Bdisclosed funding
1unicorns
310have raised
FLIAR INTELLIGENCE · ONCOLOGY × MASSACHUSETTS
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
6.2Mcombined LinkedIn audience
94%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Moderna Developer of mRNA-based therapeutics for a wide range of diseases 82Tech top 11%Funding top 15%Market top 22%Partners top 25% All 12 signals ▾Techtop 11% Fundingtop 15% Markettop 22% Partnerstop 25% Talenttop 25% Newstop 31% Moattop 32% Patentstop 34% Globaltop 38% Innovationtop 39% Growthbottom 49% Fin. healthbottom 48% Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) rank vs industry peers · Fliar Intelligence Index 82/100 | $2.8B | 17 mo ago | 1,312 | Robert Langer Co-Founder | Apple iCloud MailMicrosoft 365TypeScript+24 | 31 patents Patents concentrated in health & consumer products | 1 internship |
| 2 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 17 mo ago | 75 | Gevorg Grigoryan Co-Founder & CTO | Craft CMSApple iCloud MailPHP+17 | 36 patents Patents concentrated in chemistry & materials | — |
| 3 | Fog Pharmaceuticals Developer of cell-penetrating mini-proteins to target intracellular disease drivers | $531M | 27 mo ago | 97 97 → 197 (+103%) · sector median +22% | — | — | — | 1 partnership |
| 4 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +22% | Paul-Albert König Co-Founder and Sr. Director Biology | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 5 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | Garo Armen Chairman & CEO | WordPressMySQLMariaDB+19 | — | — |
| 6 | Scorpion Developer of drugs for the treatment of cancer | $420M | 13 mo ago | 62 | — | — | — | — |
| 7 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 11 mo ago | 67 | Andrew Schiermeier Chief Executive Officer | WordPressApple iCloud MailMySQL+16 | — | — |
| 8 | Aktis Oncology Developer of radiopharmaceuticals for solid tumor cancers | $336M | 20 mo ago | 15 | — | WordPressMySQLPHP+15 | 26 patents Targeted cancer therapeutics using engineered miniprotein ligands and conjugates | — |
| 9 | Parabilis Medicines Developer of peptide therapeutics for the treatment of severe diseases 55Funding top 13%Growth top 35%Moat top 37%Patents top 39% All 9 signals ▾Fundingtop 13% Growthtop 35% Moattop 37% Patentstop 39% Innovationtop 43% Globaltop 50% Talentbottom 49% Techbottom 43% Marketbottom 40% Funding: Raised $305M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $305M | 5 mo ago | — | Mathai Mammen CEO | WordPressApple iCloud MailMySQL+19 | 11 patents Design and synthesis of stapled peptide therapeutics for targeted drug delivery | — |
| 10 | Be Bio Developer of B cell therapies for multiple therapeutic areas 50Funding top 22%Moat top 31%Market top 48%Global bottom 36% All 4 signals ▾Fundingtop 22% Moattop 31% Markettop 48% Globalbottom 36% Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $264M | 17 mo ago | 103 | — | — | — | — |
| 11 | Alpha-9 Oncology Developer of radiopharmaceuticals for the treatment of cancer | $261M | 19 mo ago | — | David Hirsch CEO | WordPressApple iCloud MailMySQL+24 | — | — |
| 12 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 16 mo ago | 24 24 → 40 (+67%) · sector median +22% | — | WordPressMySQLPHP+13 | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 13 | Xilio Therapeutics Developer of immunotherapies for the treatment of cancer 67Funding top 25%Growth top 27%Moat top 28%Fin. health top 41% All 9 signals ▾Fundingtop 25% Growthtop 27% Moattop 28% Fin. healthtop 41% Markettop 43% Techtop 45% Talentbottom 49% Newsbottom 46% Globalbottom 39% Funding: Raised $233M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Headcount 30 → 72 (+140%) across vintages · Revenue +590% YoY rank vs industry peers · Fliar Intelligence Index 67/100 | $233M | 16 mo ago | 72 72 → 96 (+33%) · sector median +22% | Rene Russo CEO | WordPressDrupalMySQL+31 | — | — |
| 14 | CervoMed Developer of therapeutics for neurodegenerative diseases | $209M | 15 mo ago | 13 13 → 20 (+54%) · sector median +22% | John Alam Co-Founder & CEO | DrupalPHPBootstrap+21 | — | — |
| 15 | Affini-T Therapeutics Developer of T-cell therapies against oncogenic driver mutations | $193M | 22 mo ago | 97 | Jak Knowles Co-founder | WordPressApple iCloud MailMySQL+17 | — | — |
| 16 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | — | Sanjaya Singh Founder & Chief Scientific Officer | GSAPReactGatsby+15 | — | — |
| 17 | Tango Therapeutics Developer of drugs for the treatment of cancer 72Funding top 21%News top 21%Growth top 24%Talent top 33% All 10 signals ▾Fundingtop 21% Newstop 21% Growthtop 24% Talenttop 33% Fin. healthtop 41% Techtop 44% Markettop 45% Partnerstop 45% Moatbottom 49% Globalbottom 37% Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $165M | 7 mo ago | 140 140 → 157 (+12%) · sector median +22% | Barbara Weber Md President and CEO | DrupalPHPZURB Foundation+21 | — | — |
| 18 | Lumicell Diagnostics Developer of fluorescence-guided imaging technologies to help surgeons detect residual cancer tissue during… | $163M | 13 mo ago | 41 41 → 62 (+51%) · sector median +22% | Moungi Bawendi Co-Founder | WordPressMySQLPHP+22 | — | 1 launch · 1 award |
| 19 | Vigil Developer of therapeutic solutions for treating multiple neurodegenerative diseases | $140M | 23 mo ago | 56 | Ivana Liebisch CEO & President | — | — | — |
| 20 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | Daniel Getts Co-Founder & CEO | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 21 | Akamis Bio Developer of therapeutics for the treatment of colorectal cancer | $119M | 18 mo ago | 81 | Howard Davis CEO | WordPressMySQLPHP+14 | — | — |
| 22 | Aprea Developer of small molecule therapeutics targeting tumor suppressor proteins 40Funding top 18%Growth top 30%News top 38%Moat top 48% All 7 signals ▾Fundingtop 18% Growthtop 30% Newstop 38% Moattop 48% Globalbottom 42% Techbottom 35% Marketbottom 25% Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $113M | 6 mo ago | 13 | — | WordPressMySQLPHP+15 | — | — |
| 23 | Sherlock Provider of a diagnostic platform for DNA and RNA detection 62Growth top 13%Funding top 22%Talent top 28%Moat top 41% All 9 signals ▾Growthtop 13% Fundingtop 22% Talenttop 28% Moattop 41% Patentsbottom 46% Innovationbottom 41% Marketbottom 39% Globalbottom 37% Newsbottom 34% Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $111M | 12 mo ago | 33 | David Walt Co-Founder | — | 5 patents Remote health monitoring systems that detect critical vitals and trigger emergency interventions | — |
| 24 | TRIANA Biomedicines Developer of precision medicine for the treatment of cancer 45Funding top 24%Moat top 28%Talent top 38%Patents top 41% All 9 signals ▾Fundingtop 24% Moattop 28% Talenttop 38% Patentstop 41% Newstop 43% Innovationtop 47% Techbottom 46% Marketbottom 42% Globalbottom 31% Funding: Raised $110M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $110M | 6 mo ago | 38 | Jesse Chen Co-Founder & Chief Technology Officer | Cart FunctionalitySquarespace CommerceSquarespace+19 | 21 patents Patents concentrated in chemistry & materials | 2 internships |
| 25 | Ultivue Provider of test panels for personalized cancer therapies | $105M | 23 mo ago | 92 | — | — | 97 patents Multiplexed spatial biomarker imaging and histological stain removal technologies. | — |
| 26 | Corner Therapeutics Developer of immuno-therapeutics to treat cancer 24Funding top 34%Moat top 42%Talent top 45%Global bottom 32% All 5 signals ▾Fundingtop 34% Moattop 42% Talenttop 45% Globalbottom 32% Marketbottom 31% Funding: Raised $105M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $105M | 8 mo ago | 16 16 → 28 (+75%) · sector median +22% | Andrew Bellinger Co-Founder | — | — | — |
| 27 | Strand Therapeutics Provider of platform to deliver mRNA therapeutics for multi functional treatments 64Growth top 13%Funding top 24%Moat top 31%News top 41% All 7 signals ▾Growthtop 13% Fundingtop 24% Moattop 31% Newstop 41% Talenttop 41% Globalbottom 39% Marketbottom 38% Growth: Headcount 16 → 47 (+194%) across vintages · Fresh capital in last 24 mo Funding: Raised $103M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $103M | 12 mo ago | 47 | Tasuku Kitada Co-founder | — | — | 2 awards |
| 28 | Vaxess Developer of novel vaccine formulations using silk stabilization platform | $100M | 9 mo ago | 49 | Livio Valenti Co-Founder | — | 8 patents Patents concentrated in health & consumer products | 1 job opening |
| 29 | Atavistik Developer of allosteric therapeutics for precision oncology and rare diseases 50Funding top 19%Talent top 28%Moat top 31%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 28% Moattop 31% Marketbottom 42% Globalbottom 36% Newsbottom 33% Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 3 mo ago | 33 | Ralph DeBerardinis Co-Founder | — | — | — |
| 30 | Karyopharm Biopharmaceutical company focused on developing and commercializing innovative cancer therapies 69Funding top 17%News top 26%Market top 32%Tech top 34% All 9 signals ▾Fundingtop 17% Newstop 26% Markettop 32% Techtop 34% Moattop 42% Fin. healthtop 43% Talenttop 45% Growthbottom 49% Globalbottom 49% Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $98M | 2 mo ago | 325 325 → 320 (-2%) · sector median +22% | Michael Kauffman Cofounder | WordPressApple iCloud MailMySQL+27 | — | — |
| 31 | Rgenta Developer of RNA-based therapeutics for multiple disorders 32Talent top 28%Funding top 29%Moat top 39%Global bottom 39% All 6 signals ▾Talenttop 28% Fundingtop 29% Moattop 39% Globalbottom 39% Marketbottom 28% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $90.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $90M | 12 mo ago | 11 | Zhiping Weng Co-Founder | — | — | — |
| 32 | Actithera Radiopharmaceutical company developing novel radiotherapeutics for the treatment of cancer through its unique… | $81M | 11 mo ago | — | Andreas Goutopoulos Co-Founder & CEO | WordPressMySQLPHP+19 | — | — |
| 33 | Crossbow Developer of antibody therapies for cancer treatment 42Funding top 21%Moat top 36%News top 38%Talent top 38% All 8 signals ▾Fundingtop 21% Moattop 36% Newstop 38% Talenttop 38% Innovationtop 48% Patentsbottom 49% Globalbottom 39% Marketbottom 35% Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $80M | 3 mo ago | 24 | Geraldine Paulus Co-Founder | — | 21 patents High‑precision MEMS inertial sensors and power‑efficient wireless tracking technologies | — |
| 34 | Immuneering Corporation Provider of an AI-enabled bioinformatics platform for clinical solutions | $79M | 9 mo ago | 73 73 → 60 (-18%) · sector median +22% | — | DrupalPHPZURB Foundation+25 | 45 patents MEK1/2 kinase inhibitors for oncology immunotherapy, especially pancreatic cancer treatment | — |
| 35 | Verastem Developer of small molecule inhibitors of signaling pathways for cancer therapy | $68M | 13 mo ago | 57 | Brian Stuglik CEO | DrupalApple iCloud MailPHP+27 | 213 patents Patents concentrated in health & consumer products | 1 award |
| 36 | Normunity Developer of immunotherapies for the treatment of cancer | $65M | 17 mo ago | 19 | Lieping Chen Co-Founder | — | 4 patents Therapeutic antibodies targeting KLK6, LY6K, and PLA2G10 for disease treatment | — |
| 37 | Auron Therapeutics Developer of cancer therapeutics for the treatment of blood cancer | $63M | 16 mo ago | 27 | Kate Yen Co-Founder & CEO | WebflowApple iCloud MailZendesk+11 | — | — |
| 38 | Oncimmune Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | $49M | 19 mo ago | 62 62 → 35 (-44%) · sector median +22% | Jamie Heywood Managing Director | WordPressMySQLPHP+21 | 4 patents Immunoassay development and calibration technologies for diagnostic testing | — |
| 39 | Pinetree Therapeutics Developer of disruptive therapies for oncology and infectious diseases | $40M | 7 mo ago | 9 | Hojuhn Song Co-Founder & CEO | — | — | — |
| 40 | Kernal Biologics Developer of mRNA therapeutics for immuno-oncology using deep learning technology | $35M | 8 mo ago | 18 18 → 22 (+22%) · sector median +22% | Burak Yilmaz Co-Founder | — | 27 patents Targeted lipid-based delivery systems for oncoselective cancer therapeutics | — |
| 41 | Solu Therapeutics Developer of therapeutics for oncology and immunology diseases | $31M | 14 mo ago | 9 | John Pribis Co-founder | WebflowTypekitMicrosoft Advertising+11 | — | — |
| 42 | AOA Provider of an AI-enabled early detection platform focused on womens health 45Funding top 24%Patents top 27%Talent top 28%Innovation top 33% All 8 signals ▾Fundingtop 24% Patentstop 27% Talenttop 28% Innovationtop 33% Moattop 47% Globalbottom 44% Marketbottom 21% Newsbottom 18% Funding: Raised $30.7M across 7 rounds · 7 rounds over 5 yrs (1.4/yr) Patents: 22 patents matched (strict assignee match) · 21 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $31M | 8 mo ago | 3 | Alex Fisher Co-Founder & COO | — | 22 patents Patents concentrated in health & consumer products | 1 award |
| 43 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +22% | — | WordPress Block EditorWordPressMySQL+15 | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 44 | Leap Therapeutics Developing targeted and immuno-oncology therapeutics for cancer patients 35Product top 14%Funding top 30%Innovation top 34%Tech top 49% All 10 signals ▾Producttop 14% Fundingtop 30% Innovationtop 34% Techtop 49% Moatbottom 45% Newsbottom 42% Growthbottom 39% Globalbottom 37% Marketbottom 35% Fin. healthbottom 30% Product: 4 distinct product lines · Company stage: Public Funding: Raised $24.7M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $25M | 8 mo ago | 44 | — | DrupalPHPAmazon Web Services+20 | — | — |
| 45 | General Oncology Developer of treatments for solid metastatic cancers and blood cancers 42Funding top 41%Patents top 42%Talent top 45%Innovation top 48% All 6 signals ▾Fundingtop 41% Patentstop 42% Talenttop 45% Innovationtop 48% Globalbottom 43% Techbottom 24% Funding: Raised $21.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Patents: 26 patents matched (strict assignee match) · 17 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $22M | 2 mo ago | — | Arnold Glazier Founder | WordPressMySQLPHP+10 | 26 patents Combination drug regimens for treating metastatic cancer | — |
| 46 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | Rodrigo Navarro Co-Founder & CEO & President | WordPressMySQLPHP+16 | 46 patents Lipid‑nanoparticle delivery systems for malaria vaccines and encapsulated therapeutics | 1 partnership |
| 47 | Kestrel Therapeutics Developer of targeted therapies for cancer treatment | $13M | 10 mo ago | 11 | Frank Haluska President and CEO | — | — | — |
| 48 | NED Medical Developer of embolisation-based technology for cancer treatment | $10M | 4 mo ago | — | Andrew Thoreson Co-Founder & Chief Medical Officer | — | — | — |
| 49 | Attivare Therapeutics Developer of immuno-therapeutics for oncology and infectious diseases | $7M | 6 mo ago | 8 | Ed Doherty Co-Founder & CTO | — | — | — |
| 50 | Predicta Biosciences Provider of diagnostic and therapeutic products for oncology | $5M | 8 mo ago | — | Gad Getz Co-Founder | WebflowCart Functionalitycore-js+11 | — | 2 partnerships · 1 award |
Top 12 Oncology companies in Massachusetts
#1
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Series B · Cambridge, Massachusetts · founded 2019
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 20%Patents
top 41%Innovation
top 47%Talent
bottom 49%Global
bottom 35%Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 18 patents (top 74% of patent-holders) · 17 filings since 2022 vs 1 in 2017-21
Funding rounds
- May 2026Series B$122M
Founders & team
Investors
Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments
#2
Public · Newton, Massachusetts · founded 2008 · 325 employees$98.4Mraised▾
Public · Newton, Massachusetts · founded 2008 · 325 employees
Biopharmaceutical company focused on developing and commercializing innovative cancer therapies. It leverage proprietary scientific platforms to target key mechanisms of disease and address unmet needs in oncology through clinical research and drug development programs. It focuses on addressing complex cancers by investigating innovative mechanisms of action designed to disrupt disease progression at the cellular level. Its scientific approach is built around proprietary technology platforms aimed at modulating key biological processes involved in cancer development and survival.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 17%News
top 26%Market
top 32%Tech
top 34%Moat
top 42%Fin. health
top 43%Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) · Last round Post IPO (Mar 2026)
News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Market: 325 employees (top 5% of Life Sciences) · Revenue ~$146M · ~2% of tracked Oncology revenue (20 cos, FY2026)
Audience (LinkedIn): 38k LinkedIn followers
Funding rounds
- Mar 2026Post IPO$30M
- Oct 2025Post IPO$8.8M
- Dec 2022Post IPO$165M
- Oct 2018Post IPO$22.5M
Founders & team
Investors
Foresite Capital, New Leaf Venture Partners, Delphi Ventures, Adage Capital Management, Armistice Capital, HealthCor Management
Tech stack
AosApple Icloud MailAutoptimizeBootstrapCdnjsCloudflare
#3
Series F · Cambridge, Massachusetts · founded 2016$305Mraised▾
Series F · Cambridge, Massachusetts · founded 2016
Developer of peptide therapeutics for the treatment of severe diseases. It offers a proprietary AI- and physics-based computational methods as discovery platform . It offers FOG-001 an inhibitor of β-catenin:TCF for colorectal cancers.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 13%Growth
top 35%Moat
top 37%Patents
top 39%Innovation
top 43%Global
top 50%Funding: Raised $305M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series F (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: IP moat: 11 patents · Soonicorn · 9 curated direct competitors tracked
Funding rounds
- Jan 2026Series F$305M
Founders & team
Investors
RA Capital Management, Fidelity Investments, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, Arch Venture Partners
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementDocusignDraftpress HfcmFont Awesome
#4
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees$100Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees
Developer of allosteric therapeutics for precision oncology and rare diseases. The company integrated with proprietary drug discovery platform that enables to unlock novel allosteric binding pockets and rapidly advance structural insights into small molecule therapeutics designt to unlock cryptic allosteric sites across a broad range of target classes.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 19%Talent
top 28%Moat
top 31%Market
bottom 42%Global
bottom 36%News
bottom 33%Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Mar 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Mar 2026Series B$40M
- Dec 2025Series B$120M
- Dec 2023Series A$40M
- Aug 2021Series A$60M
Founders & team
Investors
The Column Group, Lux Capital, Nextech Invest, Regeneron Ventures, RA Capital Management
#5
Series A · Boston, Massachusetts · founded 2022$165Mraised▾
Series A · Boston, Massachusetts · founded 2022
Developer of therapetics for cancer and immunological diseases. It offers multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. It has technology platform a solid tumor synergy platform and an I&I platform fornimmune regulation at a tissue-specific level.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Moat
bottom 48%Tech
bottom 47%Global
bottom 36%Market
bottom 32%Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Feb 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Adagene) announced in 12 mo
Funding rounds
- Feb 2026Series A$52M
- Jul 2024Series A$165M
Founders & team
Investors
Vida Ventures, Cormorant Asset Management, Hillhouse, Goldman Sachs Asset Management, BVF Partners, Janus Henderson Investors
Tech stack
AosCookieyesCore-JsDocusignGatsbyGodaddy
#6
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees$80Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees
Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Moat
top 36%News
top 38%Talent
top 38%Innovation
top 48%Patents
bottom 49%Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents · Soonicorn
News: 3 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Series B$77M
- Sep 2025Series A$30.2M
- Jul 2023Series A$80M
Founders & team
Investors
Pfizer, Polaris Partners, BVF Partners, Mirae Asset Venture Investments, Mirae Asset, Lilly
#7
Public · Cambridge, Massachusetts · founded 2010 · 1312 employees$2.8Braised▾
Public · Cambridge, Massachusetts · founded 2010 · 1312 employees
Developer of mRNA-based therapeutics for a wide range of diseases. The company produces human proteins, antibodies, or vaccines inside patient cells, which are in turn active intracellularly or secreted. The company is also developing vaccines in different disease areas such as infectious diseases, cancer, rare diseases, and COVID-19.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Tech
top 11%Funding
top 15%Market
top 22%Partners
top 25%Talent
top 25%News
top 31%Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses · Devops: Envoy, Nginx
Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) · Last round Grant (prize money) (Jan 2025)
Market: 1,312 employees (top 7% of Sustainability Tech) · Revenue ~$1.9B · Top-5,000,000 web property
Audience (LinkedIn): 791k LinkedIn followers — 12.7% of this cohort's audience
Funding rounds
- Jan 2025Grant (prize money)$590M
- Jul 2024Grant (prize money)$176M
- Oct 2020Grant (prize money)$56M
- May 2020Post IPO—
Founders & team
Investors
ADIA, BB Biotech, Julius Baer, Sequoia Capital, Fidelity Investments, Viking Global Investors
Tech stack
AccessibeAmazon CloudfrontAmazon SesAmazon Web ServicesApolloApple Icloud Mail
#8
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Public · Cambridge, Massachusetts · founded 2015 · 51 employees
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 16%Patents
top 16%News
top 28%Moat
top 29%Growth
top 31%Partners
top 32%Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21
Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 · Latest publication 2026
News: 16 BI events in 12 mo (of 40 tracked, 7 types) · +45% YoY · Top themes: Board, Leadership, Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
Investors
MDB Capital
Tech stack
Google AnalyticsGoogle Font ApiJqueryJquery MigrateModernizrMysql
#9
Public · Boston, Massachusetts · founded 2003 · 13 employees$113.2Mraised▾
Public · Boston, Massachusetts · founded 2003 · 13 employees
Developer of small molecule therapeutics targeting tumor suppressor proteins. The company focuses on p53, a tumor suppressor protein that induces cell cycle arrest or cell death. The company's lead candidate is APR-246, that acts by reactivating mutant and defective native p53, leading to tumor cell death. The company is also developing APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 18%Growth
top 30%News
top 38%Moat
top 48%Global
bottom 42%Tech
bottom 35%Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Post IPO (Dec 2025)
Growth: Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 31 tracked, 5 types) · +33% YoY · Top themes: Earnings, Announcements, Funding
Funding rounds
- Dec 2025Post IPO$3.1M
- Mar 2024Post IPO—
- Feb 2023Grant (prize money)$2M
- Feb 2019Series C$5.7M
Investors
Nantahala Capital Management, DAFNA Capital Management, Exome Asset Management, Sphera Fund, Stonepine, Janus Henderson Investors
#10
Public · Cambridge, Massachusetts · founded 2017 · 140 employees$165Mraised▾
Public · Cambridge, Massachusetts · founded 2017 · 140 employees
Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 21%News
top 21%Growth
top 24%Talent
top 33%Fin. health
top 41%Tech
top 44%Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Post IPO (Oct 2025)
News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Headcount 110 → 140 (+27%) across vintages · Revenue +48% YoY · Web rank 10,000,000 → 5,000,000 YoY
Audience (LinkedIn): 24k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$15M
- Aug 2023Post IPO$80M
- Aug 2020Series B$50M
- Apr 2020Series B$60M
Founders & team
Investors
Casdin Capital, Boxer Capital, Third Rock Ventures, Gilead, Tavistock Group, Roche
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#11
Public · Cambridge, Massachusetts · founded 2018 · 108 employees$503.2Mraised▾
Public · Cambridge, Massachusetts · founded 2018 · 108 employees
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 12%Growth
top 13%Talent
top 28%Moat
top 31%Tech
bottom 46%Market
bottom 45%Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Jun 2025)
Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Jun 2025Series D$214M
- Oct 2023Series C$117.2M
- Oct 2022Series B$168M
- Dec 2021Series A$218M
Founders & team
Investors
General Catalyst, Alexandria, Walleye, Catalio Capital Management, GreatPoint Ventures, SVB Securities
Tech stack
Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCookieyesCore-Js
#12
Public · Lexington, Massachusetts · founded 1994 · 533 employees$440.7Mraised▾
Public · Lexington, Massachusetts · founded 1994 · 533 employees
Developer of immunotherapies to treat cancer. The company's portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 20%Tech
top 34%Product
top 35%Market
top 37%Moat
top 44%Partners
top 45%Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) · Last round Post IPO (Jun 2025)
Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly · Devops: Nginx, Varnish
Product: 0 product launch events in 12 mo · Company stage: Public
Audience (LinkedIn): 45k LinkedIn followers
Funding rounds
- Jun 2025Post IPO—
- Jul 2020Post IPO$35M
- Jan 2019Post IPO$30M
- Oct 2018Post IPO$40M
Founders & team
Investors
Betta Pharmaceuticals, HealthCare Royalty Partners, Incyte, Zynext Ventures, Grazia Equity, Advent Life Sciences
Tech stack
CloudflareComplianzDocusignElementorFancyboxFastly
Funding & investor landscape
$29.8Btotal disclosed funding
311companies funded
1,163disclosed rounds
5rounds last 90 days
Most active investors
Atlas Venture24 rounds
Notable founders
Daniel Getts
Co-Founder & CEO · CREATE Medicines
Michael Kauffman
Cofounder · Karyopharm
Richard Paulson
President and Chief Executive Officer · Karyopharm
Mathai Mammen
CEO · Parabilis Medicines
Ralph DeBerardinis
Co-Founder · Atavistik
Jared Rutter
Co-Founder · Atavistik
Sanjaya Singh
Founder & Chief Scientific Officer · Third Arc Bio
Peter Lebowitz
CEO · Third Arc Bio
Geraldine Paulus
Co-Founder · Crossbow
Briggs Morrison
CEO · Crossbow
Robert Langer
Co-Founder · Moderna
Kenneth Chien
Co-Founder · Moderna
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Oncology in Massachusetts is moving
A read on the academic research around Oncology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 462 papers.
Massachusetts General Hospital, MIT, and UMass Chan lead optimistic immunotherapy and CAR-T cell research, with biomarkers and immune responses dominating 590 breakthrough/advancement papers versus 39 concerns.
462 papers · stance +0.60 · 42% breakthrough · 9% concern
top institutions
- Massachusetts General Hospital281
- Massachusetts Institute of Technology131
- University of Massachusetts Chan Medical School40
- University of Massachusetts Amherst22
- Massachusetts Eye and Ear Infirmary11
leading researchers
Rakesh K. Jain · Kelly D. DeMarco · Griffin Kane · Katherine C. Murphy · Dan G. Duda · Howard L. Kaufman
prism intelligence · tone & topics
98% positive · 0% critical tone
PharmaceuticalsBiotechnologyClinical TrialsMedical ResearchHealthHealthcare
▲
Breakthroughs182 · 39%
▲ 36%→41% share
▲1.1× share momentum1 median citations84% since 2021mostly methods-led
Tumor microenvironment breakthroughs are surging — papers rose from 12 to 72, with cytotoxic T cell research newly emerging at 19 papers.
rising sub-themes (early→recent)
- Immune system5→66
- Tumor microenvironment12→72
- Cancer research13→62
- Immunotherapy5→48
- Cancer3→24
Newly emergingCytotoxic T cell 0→19 · Pancreatic cancer 0→14 · Blockade 0→11
Landmark Multistage nanoparticle delivery system for deep penetration into tumor tissue · 1,044 cites
◆
Advancements212 · 46%
▼ 54%→44% share
▼0.8× share momentum3 median citations77% since 2021mostly empirical
Tumor microenvironment advancement research intensified sixfold — from 17 to 86 papers — now the dominant advancements sub-topic in Massachusetts oncology.
rising sub-themes (early→recent)
- Tumor microenvironment17→86
- Immune system9→63
- Immunotherapy10→60
- Cancer research19→59
- Cancer3→26
Newly emergingTranscriptome 0→7 · Downregulation and upregulation 0→7 · In vivo 0→6
Landmark Normalization of the Vasculature for Treatment of Cancer and Other Diseases · 1,541 cites
▼
Concerns39 · 8%
▲ 7%→8% share
▲1.1× share momentum6 median citations79% since 2021mostly reviews
Immunotherapy safety concerns are rising sharply — from 1 to 21 papers — with blockade and cytokine risk topics newly emerging.
rising sub-themes (early→recent)
- Immunotherapy1→21
- Immune system1→11
- Cancer immunotherapy1→10
- Tumor microenvironment1→8
- Cancer1→7
Newly emergingBlockade 0→6 · Cytokine 0→4 · Clinical trial 0→3
Landmark Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation · 972 cites
Common questions
How many Oncology companies are there in Massachusetts, United States?
Radar tracks 416 indexable Oncology companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Massachusetts, United States?
The Oncology companies in Massachusetts, United States on this list have raised a combined $29.8B in disclosed equity funding across 311 funded companies.
Which is the highest-funded Oncology company in Massachusetts, United States?
Moderna is the highest-funded Oncology company in Massachusetts, United States, with $2.8B in disclosed equity funding.
How many Oncology companies in Massachusetts, United States are funded?
311 of the 416 Oncology companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Massachusetts, United States?
1 Oncology company in Massachusetts, United States on this list is valued at $1B or more.
Who are the top investors in Massachusetts, United States Oncology companies?
The most active investors in Massachusetts, United States Oncology companies on this list include HHS, RA Capital Management, Atlas Venture, Alexandria, Casdin Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.